Publication:
Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: Use of simultaneous measurement by high performance liquid chromatography and bioassay

dc.contributor.authorP. Teja-Isavadharmen_US
dc.contributor.authorF. Nostenen_US
dc.contributor.authorD. E. Kyleen_US
dc.contributor.authorC. Luxemburgeren_US
dc.contributor.authorF. Ter Kuileen_US
dc.contributor.authorJ. O. Pegginsen_US
dc.contributor.authorT. G. Breweren_US
dc.contributor.authorN. J. Whiteen_US
dc.contributor.otherArmed Forces Research Institute of Medical Sciences, Thailanden_US
dc.contributor.otherShoklo Malaria Research Uniten_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherWalter Reed Army Institute of Researchen_US
dc.contributor.otherUniversity of Oxforden_US
dc.date.accessioned2018-07-04T07:33:34Z
dc.date.available2018-07-04T07:33:34Z
dc.date.issued1996-01-01en_US
dc.description.abstractThe pharmacokinetic and effect kinetic properties of oral (p.o.), intramuscular (i.m.), and intrarectal (i.r.) artemether (5 mg kg-1) were compared in a crossover study in eight healthy adult volunteers. Plasma concentrations of artemether (AM) and its active metabolite dihydroartemisinin (DHA) were measured by high performance liquid chromatography with reductive mode electrochemical detection (h.p.l.c.-ECD), and plasma antimalarial activity in vitro (effect) was assessed on the same samples by a sensitive bioassay (BA). Artemether was absorbed rapidly after oral administration with a mean (95% CI) C(max) for the parent compound of 406 (249 to 561) nmol l-1and for DHA of 1009 (639 to 1379) nmol l-1with t(max) values of 1.7 (1.2 to 2.2) and 1.8 (1.4 to 2.2) h respectively. The mean (95% CI) elimination half-life of AM was 2.6 (1.8 to 3.4) h and for DHA was 1.9 (1.4 to 2.4) h. Plasma concentration and effect profiles with h.p.l.c.-ECD and BA were similar suggesting that other unidentified bioactive metabolites contributed little to antimalarial activity in vivo. Absorption was slower, more variable, and DHA concentrations were lower following the i.m. and i.r. routes of administration. The mean (95% CI) relative bioavailability compared with oral artemether in the 6 h following administration AUC (0,6h) was 25 (9 to 41)% following i.m. and 35 (10 to 60)% following i.r. artemether. These data demonstrate that oral artemether undergoes extensive first pass metabolism to the more active metabolite DHA. Plasma antimalarial activity following oral administration is significantly greater than following i.m. administration. The i.r. route of administration provided similar bioavailability to i.m. injection but there was considerable variability in absorption following both routes. Further studies are needed to determine whether i.r. artemether would be an effective treatment of severe malaria in the rural tropics in situations where oral or parenteral administration is not possible.en_US
dc.identifier.citationBritish Journal of Clinical Pharmacology. Vol.42, No.5 (1996), 599-604en_US
dc.identifier.doi10.1111/j.1365-2125.1996.tb00115.xen_US
dc.identifier.issn03065251en_US
dc.identifier.other2-s2.0-0029852334en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/17825
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0029852334&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleComparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: Use of simultaneous measurement by high performance liquid chromatography and bioassayen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0029852334&origin=inwarden_US

Files

Collections